Mini-review: medication safety of red yeast rice products

References

• Freissmuth M, Offermanns S, Böhm S. Pharmakologie und Toxikologie: Von den molekularen Grundlagen zur Pharmakotherapie. 2nd ed. Berlin (Heidelberg): Springer Verlag; 2016:499–501. German.
   Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561. doi:10.1016/S0140-6736(16)31357-527616593
   PubMed Web of Science ®Google Scholar
• Poli A, Barbagallo CM, Cicero AFG, et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacol Res. 2018;134:51–60. doi:10.1016/j.phrs.2018.05.01529859248
   PubMed Web of Science ®Google Scholar
• Banach M, Patti AM, Giglio RV, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72(1):96–118. doi:10.1016/j.jacc.2018.04.04029957236
   PubMed Web of Science ®Google Scholar
• Marchitto N, Sindona F, Fabrizio A, et al. Effect of new nutraceutical formulation with policosanol, berberine, red yeast rice, cassia nomame, astaxantine and Q10 coenzyme in patients with low-moderate dyslipidemia associated with intolerance to statins and metabolic syndrome. Minerva Cardioangiol. 2018;66(1):124–125. doi:10.23736/S0026-4725.17.04523-629264910
   PubMed Web of Science ®Google Scholar
• Santini A, Cammarata SM, Capone G, et al. Nutraceuticals: opening the debate for a regulatory framework. Br J Clin Pharmacol. 2018;84(4):659–672. doi:10.1111/bcp.1349629433155
   PubMed Web of Science ®Google Scholar
• Klimek M, Wang S, Ogunkanmi A. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. ‎Pharm Ther. 2009;34(6):313–327.
   Google Scholar
• Lin JS. An alternative treatment of hyperlipidemia with red yeast rice: a case report. J Med Case Rep. 2010;4:4. doi:10.1186/1752-1947-4-420205798
   PubMedGoogle Scholar
• Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12):830–839.19528562
   PubMed Web of Science ®Google Scholar
• Lin C-C, Li T-C, Lai M-M. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005;153(5):679–686. doi:10.1530/eje.1.0201216260426
   PubMed Web of Science ®Google Scholar
• Smith DJ, Olive KE. Chinese red rice-induced myopathy. South Med J. 2003;96(12):1265–1267. doi:10.1097/01.SMJ.0000100117.79718.DC14696880
   PubMed Web of Science ®Google Scholar
• Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008;66(4):572–574. doi:10.1111/j.1365-2125.2008.03224.x18637891
   PubMed Web of Science ®Google Scholar
• Polsani VR, Jones PH, Ballantyne CM, Nambi V. A case report of myopathy from consumption of red yeast rice. J Clin Lipidol. 2008;2(1):60–62. doi:10.1016/j.jacl.2007.12.00521291717
   PubMed Web of Science ®Google Scholar
• Tonner PH, Hein L. Pharmakotherapie in der Anästhesie und Intensivmedizin. Berlin (Heidelberg): Springer Verlag; 2011:261–262. German.
   Google Scholar
• Lovastatin Hexal 20 mg-Tabletten [prescribing information]. Austria codex. Österreichische Apotheker-Verlagsgesellschaft mbH 1 2019 German.
   Google Scholar
• Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74(8):1200–1201. doi:10.1097/01.TP.0000031950.34040.7912438974
   PubMed Web of Science ®Google Scholar
• Hong S-P, Yang J-S, Han J-Y, et al. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol. 2011;63(1):129–135.21189658
   PubMed Web of Science ®Google Scholar
• Choi D-H, Chung J-H, Choi J-S. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. Eur J Clin Pharmacol. 2010;66(3):285–290. doi:10.1007/s00228-009-0757-x20012601
   PubMed Web of Science ®Google Scholar
• Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170(19):1722–1727. doi:10.1001/archinternmed.2010.38220975018
   PubMed Web of Science ®Google Scholar
• Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. 2001;7(2):133–139. doi:10.1089/10755530175016418111327519
   PubMed Web of Science ®Google Scholar
• Li Y-G, Zhang F, Wang Z-T, Hu Z-B. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal. 2004;35(5):1101–1112. doi:10.1016/j.jpba.2004.04.00415336357
   PubMed Web of Science ®Google Scholar
• Chairote E-O, Lumyong S, Chairote G. Study on cholesterol lowering compounds in red yeast rice prepared from thai glutinous rice. In: International conference on the Role of Universities in Hands-on Education, Rajamangala University of Technology Lanna; 8 23–29, 2009:196–208; Chiang-Mai, Thailand. doi:10.1177/1753193408098902
   Google Scholar
• Ji X, Xu J, Wang X, et al. Citrinin determination in red fermented rice products by optimized extraction method coupled to liquid chromatography tandem mass spectrometry (LC-MS/MS). J Food Sci. 2015;80(6):T1438–T1444. doi:10.1111/1750-3841.1290025943499
   PubMed Web of Science ®Google Scholar
• BVL, BfArM. Einstufung von Rotschimmelreisprodukten. Stellungnahme der gemeinsamen Expertenkommission BVL/BfArM. 2 2016 Available from: https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/ZulRelThemen/abgrenzung/Expertenkommission/stellungnahmen/2016-02.pdf?__blob=publicationFile&v=5. Accessed 319, 2019 German.
   Google Scholar
• Mazza A, Schiavon L, Rigatelli G, Torin G, Montanaro F, Lenti S. The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Food Funct. 2018;9(7):3845–3852. doi:10.1039/c8fo00415c29951651
   PubMed Web of Science ®Google Scholar
• Spigoni V, Aldigeri R, Antonini M, et al. Effects of a new nutraceutical formulation (berberine, red yeast rice and chitosan) on non-HDL cholesterol levels in individuals with dyslipidemia: results from a randomized, double blind, placebo-controlled study. Int J Mol Sci. 2017;18(7):1498. doi:10.3390/ijms18071498
   PubMed Web of Science ®Google Scholar
• Cicero AF, Colletti A, Fogacci F, Bove M, Rosticci M, Borghi C. Effects of a combined nutraceutical on lipid pattern, glucose metabolism and inflammatory parameters in moderately hypercholesterolemic subjects: a double-blind, cross-over, randomized clinical trial. High Blood Press Cardiovasc Prev. 2017;24(1):13–18. doi:10.1007/s40292-016-0163-227339779
   PubMed Web of Science ®Google Scholar
• Li Y, Jiang L, Jia Z, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One. 2014;9(6):e98611. doi:10.1371/journal.pone.009861124897342
   PubMed Web of Science ®Google Scholar
• Marazzi G, Campolongo G, Pelliccia F, et al. Comparison of low-dose statin versus low-dose statin + armolipid plus in high-intensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE trial). Am J Cardiol. 2017;120(6):893–897. doi:10.1016/j.amjcard.2017.06.01528781026
   PubMed Web of Science ®Google Scholar
• Philibert C, Bres V, Jean-Pastor MJ, et al. [Red yeast-rice-induced muscular injuries: analysis of French pharmacovigilance database and literature review]. Therapie. 2016. pii: S0040-5957(16)30054-3. French.
   Google Scholar
• Mazzanti G, Moro PA, Raschi E, Da Cas R, Menniti-Ippolito F. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017;83(4):894–908. doi:10.1111/bcp.1317128093797
   PubMed Web of Science ®Google Scholar
• Raschi E, Girardi A, Poluzzi E, et al. Adverse events to food supplements containing red yeast rice: comparative analysis of FAERS and CAERS reporting systems. Drug Saf. 2018;41(8):745–752. doi:10.1007/s40264-018-0661-329582393
   PubMed Web of Science ®Google Scholar
• Ong YC, Aziz Z. Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. J Clin Pharm Ther. 2016;41(2):170–179. doi:10.1111/jcpt.1237426956355
   PubMed Web of Science ®Google Scholar
• Dobremez V, Serra A, Grosset-Janin D, Dopter A, Pineau-Blondel E, Ruel J-H. Myasthenia gravis exacerbation after red yeast rice use. Rev Neurol (Paris). 2018;174(7–8):577–578. doi:10.1016/j.neurol.2017.08.00630017101
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen P. A case of erectile dysfunction induced by red yeast rice in lipid-lowering therapy. Phytother Res. 2018;32(5):953–954. doi:10.1002/ptr.602529356231
   PubMed Web of Science ®Google Scholar
• BfArM. Pressemitteilung 3/16 – bfArM warnt erneut vor Red Rice-Nahrungsergänzungsmitteln: produkte ab einer Tagesdosis von 5 mg Monakolin K sind als Arzneimittel einzustufen. 2016 Available from: https://www.bfarm.de/SharedDocs/Pressemitteilungen/DE/2016/pm3-2016.html. Accessed 319, 2019 German.
   Google Scholar
• FDA. FDA warns consumers to avoid red yeast rice products promoted on internet as treatments for high cholesterol products found to contain unauthorized drug. 8 09, 2007 Available from: https://wayback.archive-it.org/7993/20161022045125/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm108962.htm. Accessed October 05, 2018.
   Google Scholar
• Swissmedic. Vermarktung von Präparaten mit Monascus purpureus (Rotschimmelreis, rote Reishefe) ist in der Schweiz nicht zulässig. 2 28, 2014 Avaliable from: https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/abrenzungsfragen/vermarktung_von_praeparatenmitmonascuspurpureusrotschimmelreisro.pdf.download.pdf/vermarktung_von_praeparatenmitmonascuspurpureusrotschimmelreisro.pdf. Accessed 319, 2019 German.
   Google Scholar
• Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med. 2006;145(6):474–475.16983142
   PubMed Web of Science ®Google Scholar
• Stephan K. Red rice – Wirkungen und Nebenwirkungen von Produkten aus Rotschimmelreis. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) Bulletin zur Arzneimittelsicherheit. 2016;(2):6–11. Avaliable from: https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Bulletin/2016/2-2016.pdf?__blob=publicationFile&v=5. Accessed March 19, 2019. German.
   Google Scholar